Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
The collaboration is focused on overcoming a major limitation in existing cancer drugs
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The decision was driven by results from the Phase III CAPItello-281 trial,
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
The addition of the Halcyon system represents a significant milestone in the hospital’s oncology services
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
A one-shot gene-editing cholesterol therapy could soon be a reality
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
